For the novel therapeutic agents, for the patients.

We are performing research to identify novel molecular targets in the body which can be applied to develop therapeutic agents. Our research is principally based on pharmacology and pharmacokinetics. The ultimate goal of our research is solely to controbute to the development of pharmacotherapeutics for the patients and to overcome variou diseases.

information

• February 8, 2021
  Original paper was accepted:
  Futatsugi A, Masuo Y, Kato Y. Effects of Probenecid on Hepatic and Renal Disposition of Hexadecanedioate, an Endogenous Substrate of Organic Anion Transporting Polypeptide 1B in Rats. J Pharm Sci 110(5): 2274-2284, 2021.

• December 4, 2020
  New comers (3rd year students) joined our laboratory.

• September 8, 2020
  Original paper was accepted:
  Masuo Y, Fujita K, Mishiro K, Seba N, Kogi T, Okumura H, Matsumoto N, Kunishima M, and KATO Y. 6-Hydroxyindole is an endogenous long-lasting OATP1B1 inhibitor elevated in renal failure patients. Drug Metab Pharmacokinet 35(6): 555-562, 2020

• August 15, 2020
  Original paper was accepted:
  Nishiyama M, Nakamichi N, Yoshimura T, Masuo Y, Komori T, Ishimoto T, Matsuo JI, Kato Y. Homostachydrine is a xenobiotic substrate of OCTN1/SLC22A4 and potentially sensitizes pentylenetetrazole-induced seizures in mice. Neurochem Res 45(11): 2664-2678, 2020.

• June 24, 2020
  Original paper was accepted:
  Taguchi T, Masuo Y, Futatsugi A, Kato Y. Static model-based assessment of OATP1B1-mediated drug interactions with preincubation-dependent inhibitors based on inactivation and recovery kinetics. Drug Metab Dispos 48(9): 750-758, 2020.

• April 21, 2020
  Original paper mainly performed by collaborators was accepted:
  Danoy M, Poulain S, Tauran Y, Arakawa H, Mori D, Kido T, Kusuhara H, Araya K, Kato Y, Miyajima A, Plessy C, Sakai Y, Leclerc E. Analysis of hiPSCs differentiation toward hepatocyte-like cells upon extended exposition to oncostatin. Differentiation 114: 36-48, 2020.

• March 31, 2020
  Original paper was accepted:
  Sarashina A, Chiba K, Tatami S, Kato Y. Physiologically based pharmacokinetic model of the DPP-4 inhibitor linagliptin to describe its nonlinear pharmacokinetics in humans. J Pharm Sci 109(7): 2336-2344, 2020.

• February 9, 2020
  Original paper was accepted:
  Nakamichi N, Nakao S, Nishiyama M, Takeda Y, Ishimoto T, Masuo Y, Matsumoto A, Suzuki M, and Kato Y. Oral administration of the food derived hydrophilic antioxidant ergothioneine enhances object recognition memory in mice. Curr Mol Pharmacol 14(2):220-233, 2021.

• February 5, 2020
  Original paper based on collaboration study was accepted:
  Ｋubota Y, Fujita K, Takahashi T, Sunakawa Y, Ishida H, Hamada K, Ichikawa W, Tsunoda T, Shimada K, Masuo Y, Kato Y, and Sasaki Y. Higher systemic exposure to unbound active metabolites of regorafenib is associated with short progression-free survival in colorectal cancer patients. Clin Pharmacol Ther 14(2): 220-233, 2021.

• 
  
  
  Go to the Old TopPage

Updated : July 6, 2021
このページの先頭へ